The proprietary Eveliqure vaccine technology platform is based on a live attenuated Shigella vaccine strain able to induce broad protection against shigellosis due to targeted genetic mutations   These unique characteristics are due to specific mutations introduced into the Shigella strain: deletion of the serotype-determining LPS O-antigen results in an increased immune response to shared minor antigens, and inactivation of the type III secretion system  renders the vaccine strain non-invasive. Additionally, a third deletion inactivates a putative enterotoxin in order to further improve the safety profile of the vaccine strain. Eveliqure has increased the stability of the vaccine strain by transposition of an essential gene from the chromosome to the Shigella's invasion plasmid to ensure heterologous antigens are retained and there is no reversion of the attenuating mutations.

​

The first product candidate, ShigETEC expresses a tandem repeat of a  fusion protein of LTB and an ST toxoid that induces neutralizing antibodies and thus protective immunity against both toxins of ETEC strains.